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Long survival in rats after multivisceral 
versus isolated small-bowel 
allotransplantation under FK 506 
N. Murase, MD, A. J. Demetris, MD, T. Matsuzaki, MD, A. Yagihashi, MD, S. Todo, MD, 
J. Fung, MD, PhD, and T. E. Starzl, MD, PhD, Pittsburgh, Pa. 
Abdominal multivisceral allotransplantation (MVTX) from Brown Norway donor rats 
to Lewis recipient rats was performed under a 14-day course of low (0.32 mg/kg) or 
high-dose (0.64 mg/kg) intramuscular FK 506 to which weekly further injections 
were added in some of the high-dose animals. With all three regimens, long survival 
was frequently achieved with good intestinal absorption and weight gain, but 
histopathologic evidence of intestinal rejection existed in the most lightly treated 
animals. The liver, stomach, and pancreas had only minor abnormalities. Rejection of 
isolated intestinal grafts was more difficult to control based on histopathologic criteria, 
and satisfactory results were obtained only with the most aggressive treatment protocol, 
suggesting that the liver in the MVTX had provided an advantage to the companion 
organs of the graft, of which the intestine was most vulnerable. Histopathologically, the 
lymphoid elements of the intestine, including the Peyer's patches, appeared to be the 
most immunogenic component of the intestine. Epithelium near lymphoid areas was 
secondarily involved with villous atrophy, cryptitis, and abscess formation. Beginning 
within 12 days in successful MVTX experiments, the lymphoreticular components of 
the graft intestine, including the Peyer's patches, lamina propria, and mesenteric 
nodes, were shown with anti-Ia monoclonal antibodies to be repopulated with recipient 
cells. This finding in grafts that appeared to be permanently accepted was surprising 
and contrary to expectations from the literature on intestinal allotransplantation. 
(SURGERY 1991;110:87-98.) 
From the Departments oj Surgery and Pathology, University Health Center oj Pittsburgh, 
University oj Pittsburgh, and the Veterans Administration Medical Center, Pittsburgh, Pa. 
THE ORGANS INCLUDED IJ\ multi visceral transplanta-
tion (MVTX) are the liver, pancreas, stomach, small 
bowel, and portions of the colon. 1 Clinical efforts to 
transplant this organ composite ultimately have failed 
for many reasons, including rejection, sepsis, and the 
development of lymphoproliferative disorders.2-4 To 
further study these and other problems, we developed a 
rat model of this operation in nonimmunosuppressed 
reci pients of syngeneic and allogeneic grafts. S M ultivis-
ceral allografts were rejected in 10 days, at about the 
same time and intensity as isolated intestinal grafts in 
the same strain combination. In contrast, isolated liver 
grafts were accepted permanently. It was concluded that 
the intestinal component of the multivisceral graft was 
the Achilles heel of this operation, that its vulnerability 
to rejection was not mitigated in untreated animals by 
the potential tolerogenic presence of the liver and that 
the privileged state of the liver was lost when it was part 
of the organ composite. However, the possibility was left 
open that a tolerogenic effect of the liver might be un-
masked under effective immunosuppression.s 
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This hypothesis was examined, with the new immu-
nosuppressive agent, FK 506, to treat recipients of mul-
tivisceral or isolated intestinal allografts. The intestine 
proved to be easier to protect from rejection as part of 
a multi visceral graft than when transplanted alone, and 
for the first time routine long-term survival could be 
achieved after MVTX. This was possible without evi-
dence of graft versus host disease (GVHD). In addition, 
it was shown that the chronically surviving multivisceral 
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Table I. Survival after MVTX and isolated SBTX 
Treatment 
Group Procedure Dose Duration 
1 MVTX None 
2 MVTX 0.32 mg/kg 14 Days 
3 MVTX 0.64 mg/kg 14 Days 
4 MVTX 0.64 mg/kg 14 Days, 
then weekly 
5 SBTX None 
6 SBTX 0.32 mg/kg 14 Days 
7 SBTX 0.64 mg/kg 14 Days 
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Surgery 
July 1997 
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]\iole: The animals with survival limes in parentheses were killed for histologic studies. These rats were in good condition at the time of death. except when indicated 
by * or ** within the parentheses. The other rats with survival times marked * or ** died in the cage or were killed because they were dying and could not be used 
for the special pathologic studies. 
or isolated intestinal recipients repopulated the non-
epithelial components of their grafts with a range of host 
cells predominantly of hematopoietic origin. These re-
sults have important clinical implications. 
MATERIAL AND METHODS 
Animals. Inbred male Lewis rats (LEW) weighing 
250 to 350 gm and Brown Norway rats (BN) weighing 
200 to 300 gm were used as recipients and donors, re-
spectively. With this strain combination, a histocom-
patibility difference exists for both major histocompat-
ibility complex (MHC) and non-MHC antigens. The 
animals (Harlan Sprague Dawley Inc., Indianapolis, 
Ind.) were maintained under standard conditions in 
conventional facilities. 
After surgery, the animals in both experimental 
groups were housed in individual cages and were given 
cefamandole nafate (20 mg/day) for 5 days after 
MVTX and for 3 days after small-bowel transplanta-
tion (SBTX). Deaths within 4 days were assumed to 
have a technical cause, and these animals were excluded 
from further study. To have 48 complete experiments, 
a total of 61 experiments were performed. The techni-
cal failure rate of 21.3% was almost equally distributed 
between the MVTX and SBTX experiments. 
Operations 
MVTX. The operation has been described pre-
viously. 5 After recipient evisceration, an en bloc graft 
including the liver, pancreas, stomach, omentum, small 
intestine, and colon was orthotopically transplanted, 
with vascular anastomoses between the donor and 
recipient suprahepatic vena cava, infrahepatic vena ca-
va, and aorta with an interposed small aortic graft. 
Gastrointestinal continuity was restored proximally by 
gastrogastrostomy and distally by anastomosis of the 
donor and recipient colons. 
SBTX. The recipient small bowel was resected, in-
cluding the mesenteric lymph nodes. The donor small 
bowel from the ligament of the Trietz to the ileocecal 
valve was isolated on its vascular pedicle. 5 The graft su-
perior mesenteric artery was left in continuity with a 
segment of the donor aorta, which was anastomosed to 
the recipient infrarenal aorta. The portal vein continu-
ation of the superior mesenteric vein was retained with 
the graft and anastomosed to the recipient inferior vena 
cava. Intestinal continuity was restored by proximal and 
distal intestinal anastomoses. 
Treatment and experimental design. All animals 
were given daily intramuscular injections of FK 506, 
that had been dissolved in a carrier solvent (HCO-60 
D-mannitol; Fujisawa Pharmaceutical Co. Ltd., Osaka, 
Japan) and diluted in normal saline. Three dose sched-
ules were used (Table I): (1) 0.32 mg/kg for 14 days, 
(2) 0.64 mg/kg for 14 days, and (3) 0.64 mg/kg for 14 
days followed by weekly injections of 0.64 mg/kg to day 
200. Treatment was started at the completion of 
surgery. The FK 506 doses used were modest because 
in earlier studies in LEW rats the optimal intramuscu-
lar dose was 1.28 mg/kg. 6 
Nutrition and intestinal absorption. Body weight 
and activity were recorded daily for the first 2 weeks and 
twice a week thereafter. 
Maltose absorption was determined by the measure 
of change in blood glucose after an enteral maltose 
challenge. The intestinal absorption of maltose requires 
the enzyme disaccharidase in the mucosal brush border 
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Fig. 1. Body weight (mean) after transplantation for each treatment group. Weight gain was significantly better 
(p < 0.05 Student t test) in the pooled MVTX animals versus pooled SBTX animals at the times indicted (*) 
and also in the low dose experiments at the single time noted. 
for the breakdown of maltose in glucose and active glu-
cose absorptionJ Before challenge, the animals were 
fasted for 9 hours but were allowed free access to water. 
The maltose was dissolved in 0.45% saline at a concen-
tration of 1 gm/ml and administered at a dose of 3 gm/ 
kg body weight by a gastric gavage tube. Blood glucose 
levels were measured with a glucose analyzer (Glucom-
eter 2; Miles Laboratories Inc., Elkart, Ind.) before and 
15,30,45,60,90, and 120 minutes after maltose load-
ing. Each sample required one drop of capillary blood 
from the tail. 
Pathologic studies. For routine histologic studies, 
the tissues were fixed in neutral buffered formalin, em-
bedded in paraffin, sectioned at 4 ~mI and stained with 
hematoxylin and eosin. 
Tissues for special immunohistochemical studies were 
immediately frozen in optimal cold temperature com-
pound (Tissue-Tek; Miles Laboratories Inc.). To de-
termine the origin of the lymphoid tissues in the graft, 
immunohistochemical studies were done with immu-
noperoxidase techniques on a variety of allograft and 
recipient tissues. A mouse monoclonal anti-rat class II 
MHC antibody (L-21-6)8 was used, which reacts with 
an Ia determinant present on the tissues of several 
strains of rats including the recipient strain (LEW) but 
not the donor strain (BN).8 Six microns cryostat sections 
were cut, fixed in cold acetone for 5 minutes, and air 
dried overnight. Staining was performed with a three-
step avidin-biotin complex procedure. Before incuba-
tion with the primary antibody, endogenous peroxidase 
activity was quenched by reacting the tissue with 0.6% 
hydrogen peroxidase in methanol for 5 minutes. Then, 
the slides were washed in buffer and reacted with the 
primary antibody for 45 minutes, followed by a buffer 
wash. Next, the tissues were incubated with a biotiny-
lated rat anti-mouse F(aoh fragment and washed again. 
Finally, the tissues were reacted with an avidin-biotin 
complex, and color development was obtained with 
aminoethylcarbazole. Three sets of controls were used: 
(1) the primary antibody was omitted, to rule out 
endogenous peroxidase activity; (2) the complete proce-
dure was applied to BN specimens from control rats to 
confirm our previous observations8 that the primary 
antibody did not bind to tissues of this strain (negative 
control); and (3) the distribution of staining in normal 
Lewis rat tissues was confirmed to be typical of class II 
MHC antigens (positive control). 9 
The complete pathologic studies were performed in 
seven long-term survivors, which were killed between 
100 and 200 days after transplantation (Table I). In the 
MVTX experiments, samples were obtained from the 
graft stomach, small bowel, cecum, colon, mesenteric 
lymph nodes, pancreas, and liver. Recipient tissue sam-
ples were of thymus, thoracic lymph nodes, lung, heart, 
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Fig. 2. Maltose absorption test (mean ± SD) of MVTX and SBTX recipients with short term high dose FKS06 
treatment. 
kidney, and skin. In the SBTX experiments, the same 
recipient tissues were studied, and graft samples were 
taken from jejunum, ileum, and mesenteric lymph 
nodes. In both kinds of allografts, special attention was 
paid to the Peyer's lymphoid patches. 
RESULTS 
Survival. MVTX and SBTX recipients that did not 
receive immunosuppressive therapy died from acute re-
jection and consequent small-bowel perforation and/or 
sepsis after a median survival of 10 and 12 days, respec-
tively. These operations (Table I; groups 1 and 5), 
which have been reported previously,S were performed 
contemporaneously with those in the FK 506 treatment 
groups of this study. Extended survival of MVTX re-
cipients (groups 2 to 4) and SBTX recipients (groups 6 
to 8) was accomplished frequently with FK 506 treat-
ment. This survival was not significantly different with 
variable drug doses or with one operation versus the 
other (Table I). However, subtle differences were noted 
in clinical behavior and in the pathologic observations. 
MVTX recipients. With two exceptions (both in 
group 3), all of the FK 506-treated MVTX rats that 
were alive at the end of 4 days survived for at least 155 
days or until they were killed for tissue studies (Table 
I). The two early deaths in group 3 were from an ileus 
and chylothorax. All of the dose schedules were effective 
(groups 2 to 4; Table I). The five animals that were 
killed 114 to 203 days after surgery for tissue studies 
were healthy, and their grafts were grossly normal 
(Table I). Their deaths for pathologic studies distorted 
the aforementioned survival comparisons. 
SBTX recipients. In contrast to the MVTX exper-
iments, the results were markedly affected by FK 506 
dose schedules. Three (50%) of the six rats given 0.32 
mg/kg/day for 2 weeks (group 6) and four (40%) of 10 
rats given double this dose for 2 weeks (group 7) died 
or were killed because they were dying after 42 to 163 
days. The gross causes of death or terminal illness were 
intestinal obstruction, abscess formation, and adhesions 
that were highly concentrated at or near the intestinal 
anastomoses. Keys for the diagnosis in individual ani-
mals are indicated in the footnotes of Table I. The graft 
intestinal walls were thickened, and Peyer's patches 
could not be found. The graft mesentery was thickened 
with lymphatic congestion and white fibrotic lymph 
nodes. An apparently healthy rat from the higher dose 
group 7 also had swollen bowel and thickened mesen-
tery when killed after 107 days, whereas the graft ap-
peared normal at 109 days in a rat from group 8 that 
was treated with further weekly FK 506 after an initial 
14-day high-dose course. 
Body weight. In contrast to the SBTX recipients that 
usually resumed a regular diet in 1 or 2 days, the 
MVTX rats required food withdrawal for 4 days. The 
pooled MVTX rats lost weight to a significantly greater 
extent than the SBTX rats for each of the first 9 days, 
but after 8 weeks their weight was significantly higher 
than the pooled SBTX rats (Fig. 1). 
MVTX. These animals gained weight (Fig. 1) and 
were active. The animals given extended FK 506 ther-
apy (group 4) had a better weight gain than those with 
short-term treatment (groups 2 and 3). 
SBTX. Weight gain in the SBTX rats was less sat-
isfactory than in the MVTX rats. The best SBTX 
weight gain was in rats given extended high-dose FK 
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Fig. 3. At 203 days after MVTX under high dose continuous FK 506 (group 4). A, Essentially normal small 
intestine and intact Peyer's patches. (Hematoxylin-eosin; original magnirlcation X48. ) B, Pancreas with mild 
periductular mononuclear infiltrate (arrow). (Hematoxylin-eosin; original magnification X125.) 
506 treatment (group 8; Fig. 1). Group 6 and 7 SBTX 
rats had diarrhea. 
Maltose absorption test. Sixteen animals were stud-
ied, including seven unoperated LEW, four MVTX 
recipients from group 3, and five SBTX recipients from 
group 7, between 107 and 203 days after transplanta-
tion (Fig. 2) . Fifteen minutes after maltose loading, 
peak blood glucose levels were higher in the normal 
LEW than in those of the experimental groups, but the 
differences were not statistically significant (p > 0.05; 
Student t test). Blood glucose levels returned to normal 
within 120 minutes . Minor differences between the ex-
perimental and control animals were observed at vari-
ous time points (Fig. 2). 
Histopathologic studies. Histopathologic studies 
were performed only if fresh tissues could be obtained 
at death . The animals appeared healthy at the time of 
death, except for those with ileus and chylothorax (Ta-
ble I). The data from animals used for standard histo-
pathologic studies are shown in Table II. 
Standard histopathology 
MVTX. The intestine was essentially normal in the 
group 4 MVTX rats killed 203 days after surgery after 
a 14-day course and subsequent weekly high-dose 
treatment with FK 506 (Fig. 3, A). The villi were long 
and slender with normal lamina propria, except for mild 
focal lymphatic dilatation. Peyer's patches were normal 
(Table II). The stomach was normal, and the colon 
could not be distinguished above the colocolostomy from 
below the recipient's colon. A mild periductular lym-
phocytic infiltrate was found in the pancreas (Fig. 3, B) 
and in the portal tracts of the liver, but the parenchyma 
was undisturbed. 
The findings were almost as favorable, including good 
preservation of Peyer's patches and mesenteric lymph 
nodes (Fig. 4) , in animals given a 14-day high dose 
course of FK 506 (group 3) and killed 114 to 134 days 
after surgery. However, in an animal killed 114 days 
after surgery after receiving one half this dose for 14 
days, abnormalities were detected including depletion 
and scarring of the mesenteric lymph nodes, villous 
blunting, and focal cryptitis (Table II). In this animal, 
the grafted pancreas and liver had focal lymphocyte in-
filtration, but the parenchymal architecture was not 
disturbed . 
SBTX. The only recipients with relatively satisfac-
tory results were those in group 8 treated with a 14-day 
course of high-dose FK 506 followed by weekly injec-
tions (Tables I and II). However, with all dose sched-
ules, the changes in the isolated intestinal grafts were 
more common and severe than in the intestine of the 
MVTX rats, which had received comparable treatment 
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(Table II). This was exemplified by villous blunting, 
cryptitis, and lymphoid depletion of the lamina propria 
(Fig. 5) in an animal of group 7 at 107 days that had 
been given a 14-day course of high-dose FK 506, which 
in MVTX experiments completely protected the intes-
tine (Table II). The Peyer's patches and mesenteric 
lymph nodes were particularly affected even though the 
epithelial intestinal components were still relatively in-
tact (Table II); the lymphoid components were com-
pletely replaced by scar tissue (Figs. 5 and 6). 
The intestinal grafts from the animals treated for 14 
days with low-dose FK 506 (group 6) had even more 
severe and diffuse abnor~alities 57 to 102 days after 
surgery. These specimens were obtained earlier because 
the rats had become ill as a result of the graft damage 
and were killed because of their terminal condition 
(Table I). 
Recipient tissues. Host tissues after MVTX or 
SBTX did not have consistent abnormalities of thoracic 
lymph nodes, ear skin, tongue, esophagus, heart, lung, 
and kidneys. The liver, pancreas, stomach, and colon 
after SBTX were essentially normal. Thymic medul-
lary depletion was common after both MVTX and 
SBTX. This is a known consequence of FK 506 
therapy.lo 
Immunohistochemical studies. Immunohis-
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four MVTX recipients after 12 to 203 days; three rats 
were from group 3, and one rat was from group 4. The 
findings were identical. In the liver, spindle-shaped 
cells, which were intensely positive for L-21-6, were 
noted in the portal triads (Fig. 7) immediately subjacent 
to the terminal hepatic venules and in the capsule of the 
liver. Similar cells were seen in the pancreatic intersti-
tium and capsule. A few of the mononuclear inflamma-
tory cells in the pancreas and liver were also L-21-6. 
Practically all of the cells in the lymphoid tissue of the 
intestine were L-21-6 and thus of recipient origin (Fig. 
8). Most cells in the dome region of the Peyer's patches 
were also positive, as were dendritic-shaped cells within 
the follicles. Lymphoid cells in the interfollicular T-cell 
zones did not stain for L-21-6 (Fig. BB). These repop-
ulation changes were seen as early as 12 days after 
MVTX (Fig. BA). 
DISCUSSION 
These experiments showed that with FK 506 long-
term survival can be repeatedly achieved in rats after 
MVTX across a strong histocompatibility barrier. Sys-
tematic or even sporadic success with this difficult op-
eration has not been possible in the past with any spe-
cies. FK 506, which has been shown in heterotopic! 1 and 
orthotopic!2 intestinal transplantation models to be su-
perior to cyclosporine for prevention of both rejection 
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Fig. 4. At 134 days aft er MVTX under high close FK 506 for 14 days only (group 3) . A, Normal intestine and 
Peyer's patches. (H ematox ylin-eos in ; origina l magnificat ion X48.) B, Intact mesenteric lymph node with full 
complement of lymphoid cell s. (Hematoxylin-eosin ; original magnif'ica tion X4 8.) 
and GVHD, was given daily for 2 weeks in low and 
high-dose schedules and was continued weekly in a 
subgroup of high-dose animals . Most MVTX rats with 
all of these therapeutic variations gained weight, were 
active, and (in those tested) had nea rly normal maltose 
absorption. The parenchyma in all of the constituent 
organs was well preserved. However, with the less ag-
gressive treatment regimens, the graft mesenteric lymph 
nodes were sometimes depleted of lymphoid cells; focal 
cryptitis at the base of the villi was detectable in the 
small intestine; and periductular lymphocytic infiltra-
tion was more prominent in the graft liver and pancreas 
than when heavier treatment was used. None of the an-
imals had any clinical or histopathologic evidence of 
GVHD. It is possible that the BN to LEW combination 
may not be conducive to this complication. The potent 
ability of FK 506 to prevent GVHD has been shown in 
other strain combinations. I I , 12 
Isolated small-bowel transplantation also was suc-
cessfully done, but control of rejection seemed more dif-
ficult to achieve with all of the treatment schedules than 
with MVTX. Long- term survival comparisons were 
meaningless because so many healthy MVTX rats were 
killed for histopathologic studies. Therefore, reliance 
was placed on the pathologic studies for comparisons of 
rejection. Differences between MVTX and SBTX were 
particularly evident at the lowest FK 506 doses, where 
rejection of the isolated small bowel was associated with 
severe morbidity, including diarrhea and poor weight 
gain, even though good maltose absorption was retained . 
The intestine and mesentery in these animals were 
grossly swollen. Histopathologically, the intestinal villi 
had focal necrosis and blunting, many areas of cryptitis 
(often with abscess formation), and depletion of the 
lymphocytes in the lamina propria. The lymphoid con-
tent of Peyer's patches and mesenteric lymph nodes was 
also depleted and was replaced with scar tissue to an 
extent never seen wi th comparable treatment in the in-
testine of the multivisceral grafts. In spite of higher doses 
of FK 506, many of these same morphologic changes 
were found , although less advanced, in the isolated in-
testinal grafts although the animals were clinically nor-
mal at the time of their death . The protection of the iso-
lated intestinal grafts was complete only when FK 506 
was used in high doses initially and continued weekly 
afterwards. 
These observations a re compatible with , but do not 
prove, previous claims that the liver is protective of or 
tolerogeneic for concomitantly transplanted organs. I 3. 14 
In the past, the reason for this "sanctuary" inAuence of 
the liver has been explained in several waysl 4, 1.1 of 
which one unlikely possibility that has not been ruled 
94 Murase et at. Surgery 
j uly 1991 
Fig. 5. Intestine 107 days after SBTX under high dose FK 506 ror 14 days only (group 7). The conditions of 
treatment were th e same as for the MVTX group 3 (compare with Fig. 4). A, Villous blunting , scarring at Pey-
er's patch remnant (arrow) and thickening of musculari s. (Hematoxylin-cosin; original magnification X4S.) B, 
Mucosal breakdown and intramural abscess (arrow) at site of Peyer's patch disappearance. (Hematoxylin-eosin; 
original magnifica tion magnificatoin X4S.) C, High power or abscess. (Hematoxylin-eosin; original magnifica-
tion X300.) 
out is that the other organs of a multi visceral graft 
(pancreas, stomach, duodenum, and colon) have an 
ameliorating influence. 15 An attractive recent hypothe-
sis is that excretion of soluble HLA antigens by the liver 
grafts may be responsible. 16 \Vhatever the explanation, 
the clinical implication is that intestinal transplanta-
tions in the kind of organ composites that have been 
described for patients with hepato-intestinal dis-
orders2• 3,17 may have a distinct immunologic advan-
tage, as has been suspected since the first descri ption of 
MVTX in dogs. 1 
The design of our experiments was inappropriate for 
determination of the reasons for the seeming advantage 
of the intestine in multivisceral grafts because the venous 
drainage in the MVTX rats was through the natural 
transhepatic route, whereas the venous outflow from our 
isolated intestinal grafts was into the recipient inferior 
vena cava. Because splanchnic venous blood, IH, 19 in-
cluding that from the intestine?) is hepatotrophic, the 
systemic drainage used in our SBTX rats could result 
in liver damage,20 as suggested by Schraut et al. 21 They 
showed moderate hepatic atrophy, hyperammonemia, 
and lipid and other metabolic abnormalities in host rat 
livers after SBTX experiments similar to ours. Al-
though these same metabolic changes were seen by Kol-
tun and Kirkman,22 none of these findings, including 
hepatic atrophy, could be documented by Shaffer et al. 23 
when intestinal grafts were drained systemically . 
A further question that could not be resolved by our 
experiments because of the unbalanced intestinal venous 
drainage in the MVTX and SBTX procedures is 
whether the liver modifies allograft antigens or immu-
noreactive cells in ways that mitigate rejection24 . 25 or 
GVHD.23, 26 Numerous claims have been made2 ) that 
whole organ or cell grafts drained or implanted in the 
portal vein are rejected less vigorously than those 
drained systemically. Schraut et al. 26 reported such a 
mitigating effect on intestinal grafts drained transhe-
patically , but this could not be confirmed by Shaffer et 
al. 23 Resolution of these important controversies will 
require further experiments with equivalent intestinal 
venous drainage after MVTX and SBTX. 
Whatever the results of these experiments, they 
should not invalidate the observations reported herein 
about the events of intestinal rejection, which were the 
same in MVTX and SBTX experiments although more 
pronounced in the latter. The hallmarks of chronic re-
jection have been reasonably well characterized for the 
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Fig. 6. Host (A) and graft (B) mesenteric lymph nodes from the same rat as in Fig. 5, 107 days after SBTX. 
Note the total lymphoid depletion and extensive scarring of the allograft node iLl whith remnants of the subcap-
sular sinus tu n be seen (an-ow) . (Hematoxylin-eosin; (hematoxylin-eosin; original magnification X48.) 
kidney, liver, heart, and lung, but not for the small 
bowel. The findings in the present experiments and in 
those previously reported in the absence of immuno-
suppressions allow a profile of both acute and chronic 
intestinal rejection to be drawn after either MVTX or 
SBTX. With or without immunosuppression, the first 
insult apparently is to the most immunogenic portions 
of the intestines, namely the Peyer's patches and 
regional lymph nodes. This is seen by day 6 or 7 in un-
treated animals5 and at variable times under immuno-
suppression. Villous atrophy and cryptitis near the 
Peyer's patches occur as the lymphoid tissue, including 
that of the lamina propria, is depleted. When necrosis 
and discontinuity of the epithelium occurs, a loss of the 
intestinal barrier occurs, which has been illustrated by 
permeability studies in the landmark human case of 
Grant et al. 17 Bacterial translocation through the dam-
aged and porous intestine would account for the myste-
rious and usually lethal septic complications that have 
terminated most clinical efforts at intestinal transplan-
tation. The distortion and destruction of lymph nodes 
with consequent disruption and stasis in the lymph 
drainage probably contribute to the swelling of the 
chronically rejected intestine. The epithelial component 
evidently is preserved until relatively late because good 
maltose absorption was maintained in our animals in 
Fig. 7. Replacement of intensely L-21-6+ spindle-shaped 
cells was noted in the liver of a MVTX recipient killed for 
histologic study 114 days after transplantation under trans-
plantatio nunder high dose FK 506 for 14 days only on (group 
3). These cells are probably bone marrow-derived dendritic 
cells. (L-21-6, red with hematoxylin counterstain; original 
magnification X300.); pv, Ponal vein. 
spite of gross anatomic distortion. All the while, there is 
a progressive obliteration of the lumens of mesenteric 
arteries by intimal hyperplasia, characteristic of 
"chronic" rejection of all organ allografts. 
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Fig. 8. Replacement of the donor lymphoid tissue with recipient cells. A, Twelve days after MVTX under high-
dose FK 506 for the 12 days of survival (group 3) about one half of the intestinal lymphoid cells were replaced 
(L-21-6, red; hematoxylin hemaLOxyling counterstain). B, At 114 days (group 3), most of the cells in the follicl es 
of the Peyer's patches displ ayed recipient 1a determinants. C, Same replacement in the lamina propria of the villi 
(group 3) at 134 days. (L-21-6, red ; hematoxylin counterstain; original counterstain (original magnification 
X300.) T, T-cell interfollicular zone; F, B-cell follicle . 
If our observations are verified, revISIon will be 
required about some of the assumptions on the central 
events of both rejection and (in successful transplanta-
tion) of graft acceptance. It has been assumed in most 
descriptions of intestinal rejection, including our 
own,2, 4. 27 that the appearance of alloreacti ve cells in the 
graft is strongly associated with or equivalent to rejec-
tion. 
The findings in the studies herein reported suggest 
that at some stages the opposite may be the truth in that 
repopulation with recipient cells is associated with graft 
acceptance. As early as 12 days after transplantation of 
multivisceral grafts, a major infiltration of recipient 
lymphoreticular cells had entered the lymphoid compo-
nents of the graft, including the lamina propria of the 
villi , the Peyer's patches, and the regional lymph nodes. 
Most of the lymphoreticular population in perfectly ac-
cepted grafts as late as 203 days were of recipient ori-
gin, including the spindle-shaped stromal cells, which 
were thought to be the dendritic cells so important in 
antigen presentation. These findings were consistent 
with those in earlier studies of accepted rat liver grafts 
in which lymphoid elements that had normal alloreac-
tivity against the original donor strain could be found in 
the recipient, in spite of the fact that no evidence of graft 
dysfunction was found. 2H It is highly probable that most 
of the cells of hematopoietic origin in the accepted 
MVTX and SBTX grafts had undergone this change, 
although the only ones specifically studied were those 
with Ia receptors . 
Because the demonstration of lymphoreticular repop-
ulation in our experiments was dependent on the spec-
ificity of a monoclonal antibody technique, the possibil-
ity had to be considered that the results were due to a 
staining artifact. This was ruled out with both the neg-
ative and positive controls. It was also questioned if the 
change in staining characteristics of the graft could have 
been due to the increased expression of Ia antigens of 
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donor tissue, which is known to occur during rejection 
or nonrejection related damage,29-31 rather than reflect-
ing repopulation by recipient cells. However, other ex-
periments in our laboratory on the traffic of dendritic 
cells in rejecting DA livers transplanted to BN recipi-
ents have not revealed any change in the staining of the 
BN cells in the grafts or in the recipient spleen, thymus, 
or lymph nodes.32 Aside from these observations, re-
population of the lymphoreticular cells has been shown 
in three successfully transplanted human intestinal 
grafts in which Class I HLA phenotypes of the intesti-
nal lymphoreticular tissues were shown with HLA-
specific monoclonal antibodies to become those of the 
recipient (unpublished observations). In both the rat 
and human studies, the epithelial components of the 
grafts were thought to have retained donor specificity. 
The congruence of these observations in rats and hu-
mans with different phenotype detection techniques is 
reassuring. That lymphoreticular repopulation could 
occur in humans has received little attention in spite of 
the fact that replacement of the Kupffer cell 
population31 , 33 or cells in the hepatic hilar lymph 
nodes34 has been reported under immunosuppression 
both with azathioprine or cyclosporine-based regimens. 
Thus the repopulation probably is not specific to FK 
506, but merely more easily achieved with FK 506 be-
cause of the drug's superior immunosuppressive qual-
ities during the critical induction phase when cell 
movement is occurring. 
ADDENDUM 
Documentation of the same kind of cell repopulation 
in humans that was seen in these animal experiments is 
in Iwaki Y, et a1. 35 
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